A randomized phase II trial of abiraterone, olaparib or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.

被引：5

作者：

Reichert, Zachery

Carneiro, Benedito A.

Daignault-Newton, Stephanie

Sullivan, Amanda

Feng, Felix Yi-Chung

Morgan, Todd Matthew

Tomlins, Scott A.

Chinnaiyan, Arul M.

Hussain, Maha

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Univ Michigan, Sch Med, Div Biostat, Ann Arbor, MI USA

[4] Prostate Canc Clin Trials Consortium LLC, New York, NY USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS5086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5086

引用

页数：5